Cargando…

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

Detalles Bibliográficos
Autores principales:	Moreno-Ramos, Manuel José, Sanchez-Piedra, Carlos, Martínez-González, Olga, Rodríguez-Lozano, Carlos, Pérez-Garcia, Carolina, Freire, Mercedes, Campos, Cristina, Cáliz-Caliz, Rafael, Calvo, Jerusalem, Blanco-Madrigal, Juan María, Pérez-Gómez, Ana, Moreno-Martínez, María José, Linares, Luis, Sánchez-Alonso, Fernando, Sastré, Carlos, Castrejón, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510073/ https://www.ncbi.nlm.nih.gov/pubmed/36063343 http://dx.doi.org/10.1007/s40744-022-00479-0

Ejemplares similares

Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021)

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
por: Vela, Paloma, et al.
Publicado: (2020)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
por: Bethencourt Baute, Juan José, et al.
Publicado: (2018)

Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA
por: Gaffney, Karl, et al.
Publicado: (2023)

Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?
por: Benavent, Diego, et al.
Publicado: (2020)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
por: Gudmann, Natasja Stæhr, et al.
Publicado: (2016)

Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
por: Álvaro-Gracia, José M, et al.
Publicado: (2023)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
por: Jadon, Deepak R, et al.
Publicado: (2017)

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
por: Ramonda, Roberta, et al.
Publicado: (2022)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry
por: Ciurea, Adrian, et al.
Publicado: (2023)

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2020)

A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis
por: Michelsen, Brigitte, et al.
Publicado: (2015)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
por: Michelsen, Brigitte, et al.
Publicado: (2020)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
por: Smolen, Josef S, et al.
Publicado: (2018)

Non-Physical Disease Facets in Spondyloarthritis: An ASAS Health Index-Based Analysis between Psoriatic Arthritis and Axial Spondyloarthritis
por: Queiro, Rubén, et al.
Publicado: (2022)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2017)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Caesarean section in women with axial spondyloarthritis and psoriatic arthritis: a population-based study
por: Götestam Skorpen, Carina, et al.
Publicado: (2023)

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
por: Michelsen, Brigitte, et al.
Publicado: (2023)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Antiphospholipid Syndrome Associated with Nonradiographic Axial Spondyloarthritis
por: De Carvalho, Jozélio Freire, et al.
Publicado: (2021)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3q73v3oktbd52v94am6e6pus3p